<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H1EAF1E1DFAE54436BE0D180F5419BB0A" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 1173 IH: Patients’ Right to Know Their Medication Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-02-24</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1173</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230224">February 24, 2023</action-date><action-desc><sponsor name-id="C001103">Mr. Carter of Georgia</sponsor> (for himself, <cosponsor name-id="G000592">Mr. Golden of Maine</cosponsor>, <cosponsor name-id="W000821">Mr. Westerman</cosponsor>, and <cosponsor name-id="R000576">Mr. Ruppersberger</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act regarding the patient medication information required to be included in the labeling of prescription drugs, and for other purposes.</official-title></form><legis-body id="H176B0D3A5B0C4D08B9CDF34484A2A032" style="OLC"><section id="H60D665E2039D4381806A29581943BF62" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Patients’ Right to Know Their Medication Act of 2023</short-title></quote>.</text></section><section id="H62B0915FCCF94E2789FD6B86997992BB"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress finds the following:</text><paragraph id="H1637ED1BA66B42958B15B2ECD93CB4B1"><enum>(1)</enum><text>Prescription medications are important to the health and well-being of the American public.</text></paragraph><paragraph id="H00ACC52784284850942A163E8D8D43E9"><enum>(2)</enum><text>According to the Centers for Disease Control and Prevention (CDC), 48.9 percent of Americans used at least one prescription drug in the past 30 days.</text></paragraph><paragraph id="HA52DBB0FE61D4254B94C265CA26004E6"><enum>(3)</enum><text>The utilization of prescription drugs can subject patients to adverse drug events; therefore, patient safety is of the utmost importance.</text></paragraph><paragraph id="H03E6E9FBCA044C6A83DD8565FD4C9A35"><enum>(4)</enum><text>Studies indicate that paper format patient medication information (PMI) can help protect patients and prevent the majority of costly adverse drug events.</text></paragraph><paragraph id="HD772605C229F43D3A3B66E569CE7159B"><enum>(5)</enum><text>In addition to bolstering patient safety, the mandatory use of a standardized PMI provided to all patients in nonhospital settings could reduce costs associated with emergency room visits and hospital admissions related to adverse drug events by $14.6 to $26.2 billion dollars annually.</text></paragraph><paragraph id="H97F6A015132947C1805D169945C436A2"><enum>(6)</enum><text>Many patients cannot access electronic versions of PMI, thereby necessitating a paper option.</text></paragraph><paragraph id="HC074051E4B58455EA7E5483173278EA2"><enum>(7)</enum><text>The Government Accountability Office found that relying on electronic labeling as a complete substitute for paper labeling could adversely impact public health.</text></paragraph><paragraph id="HDA5B537EB48043DC8A4AE2197382C765"><enum>(8)</enum><text>A congressionally mandated paper PMI is needed because no standardized PMI in a single page, paper copy, proven patient-friendly format is currently available to patients or required by the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301 et seq.</external-xref>).</text></paragraph></section><section id="H5A080AB055D74F2791082F911BE76C7E"><enum>3.</enum><header>Patient medication information for prescription drugs</header><subsection id="HC9C570406A4541CFA8006284543D59E1"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351 et seq.</external-xref>) is amended by inserting after section 505G (<external-xref legal-doc="usc" parsable-cite="usc/21/355h">21 U.S.C. 355h</external-xref>) the following:</text><quoted-block id="HF51004EDD39046BF815702C54838E2C8" style="OLC"><section id="HF9C9B2E18528438AB153306574CAA140"><enum>505H.</enum><header>Patient medication information for prescription drugs</header><subsection id="H4DA69516FF6448EDB453E73FCA3E20E7"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall issue regulations on the patient medication information that is required to be in the printed labeling of drugs subject to section 503(b)(1), including regulations regarding the authorship, content, format, color, printing, and dissemination requirements for such patient medication information. The Secretary shall issue final regulations pursuant to the preceding sentence not later than 1 year after the date of enactment of this section.</text></subsection><subsection id="H6C0EE035235A4C2A98A45877316AEEB7"><enum>(b)</enum><header>Content</header><text>The regulations promulgated under subsection (a) shall require that the patient medication information with respect to a drug—</text><paragraph id="H0DAB27AE074B4EDE913F36541D923099"><enum>(1)</enum><text>be scientifically accurate, include relevant patient safety information, and be approved by the Secretary;</text></paragraph><paragraph id="H4030BD33FEC24DC8A0051C539A5EDC82"><enum>(2)</enum><text display-inline="yes-display-inline">include understandable plain language, and include graphics and pictures when applicable, and be provided in a consistent, standardized format and color for all drug products, and not be promotional in tone or content, and contain at least—</text><subparagraph id="H4E280AC08A5743EBBF31CA1D551CD1CD"><enum>(A)</enum><text>the established name of the drug (or, if the drug is a biological product, the proper name of the biological product) and the national drug code for the drug;</text></subparagraph><subparagraph id="HFEA6F6B9CF0C4F47B0231B992F6281E7"><enum>(B)</enum><text>indications for use approved by the Food and Drug Administration;</text></subparagraph><subparagraph id="HD1801C65DEC94385891195BA4C660727"><enum>(C)</enum><text>general directions for proper use;</text></subparagraph><subparagraph id="HB7F33499AB0C4647B68A56F5D2A6E662"><enum>(D)</enum><text>contraindications, warnings, precautions, the most frequently occurring adverse reactions, and adverse reactions that are important for other reasons (such as because they are serious), especially with respect to certain subpopulations such as children, pregnant women, and the elderly;</text></subparagraph><subparagraph id="H0B413E7EA3A442EABA9D1298F38502D6"><enum>(E)</enum><text>measures patients may be able to take, if any, to reduce the side effects and risks of the drug;</text></subparagraph><subparagraph id="HB3E0F74628584A25A99EBA750B70266F"><enum>(F)</enum><text>information about when a patient should contact his or her health care professional;</text></subparagraph><subparagraph id="H0684EEC832D846A9BE2CC672BD7C9C2A"><enum>(G)</enum><text>instructions not to share medications, and, if applicable, key storage requirements and recommendations relating to proper disposal of any unused portion of the drug;</text></subparagraph><subparagraph id="HD8285D21B7204B84BB54C5F7F9F41946"><enum>(H)</enum><text>known clinically important interactions with other drugs, food, and other substances;</text></subparagraph><subparagraph id="HDEA3E985649148598A080DDFD7F0A9EB"><enum>(I)</enum><text>a statement of whether sufficient data are available concerning the use of the drug in specified subpopulations, such as women, pregnant women, lactating women, women and men of reproductive age, and pediatric, geriatric, racial, and ethnic minority groups;</text></subparagraph><subparagraph id="HB3CEF8F4B7CC44EF92D02DB46DD1C3C8"><enum>(J)</enum><text display-inline="yes-display-inline">the name of the manufacturer and a toll-free telephone number for consumers to contact the manufacturer of the drug; and</text></subparagraph><subparagraph id="H02EF64F717CD4DB79451C4A9BEF5F346"><enum>(K)</enum><text>a current link to Form FDA 3500B for voluntary reporting for consumers of adverse events, product problems, and product use errors (or any successor form); and</text></subparagraph></paragraph><paragraph id="H840B626EBC2843A385ABDACA2342F16B"><enum>(3)</enum><text display-inline="yes-display-inline">be provided to a patient or agent of a patient in a printed format with each prescription dispensed, such that a drug labeled for distribution shall be accompanied by printed labeling physically on or within the packaging from which the drug is to be dispensed, in an adequate supply of printed patient medication information to accommodate prescriptions dispensed therefrom.</text></paragraph></subsection><subsection id="HE44FE408E2304C5C8FA68D0C3E894816"><enum>(c)</enum><header>Timeliness, consistency, accuracy, and effectiveness</header><text>The regulations promulgated under subsection (a) shall—</text><paragraph id="HA954DF6BC93C473CACD6332BAB070DCE"><enum>(1)</enum><text display-inline="yes-display-inline">provide for timely reviews, approvals, and updates of patient medication information as new drugs and new information become available;</text></paragraph><paragraph id="H851E6BC37EB44C9AA5892FD7C5A94C71"><enum>(2)</enum><text display-inline="yes-display-inline">provide for updates when appropriate to help communicate information that is shared by similar products or drugs within classes of medication to avoid patient confusion and harm;</text></paragraph><paragraph id="H6237E8A1BA3F46BAB5355330D7DD10E8"><enum>(3)</enum><text display-inline="yes-display-inline">include specifications for language, graphics, format, color, and pictures required by subsection (b)(2), to be developed based upon documented patient research with one or more actual drug products that demonstrates improved patient learning and understanding of safe and effective medication use; and</text></paragraph><paragraph id="H348BABFBD3FE4A45B85277D36B06E3F4"><enum>(4)</enum><text>be based on a demonstrated causal connection between the enhanced patient medication information required by the regulations and improved patient medication adherence and compliance for the purpose of reducing the cost of health care and improving desired medical outcomes.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H2AADB215EE814E6DBF839A50E314A335"><enum>(b)</enum><header>Misbranding offense</header><text>Section 502 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/352">21 U.S.C. 352</external-xref>) is amended by adding at the end the following:</text><quoted-block id="H3122FEFFB5F346DA90081A132F489374" style="OLC"><subsection id="H681D570FFEF04CD48AFD60938B605A19"><enum>(gg)</enum><text>If it is a drug subject to section 503(b)(1) and patient medication information is not provided in accordance with section 505H.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section></legis-body></bill> 

